Contribute Try STAT+ Today

Merck (MRK) has a done a lot right in cancer immunotherapy, probably more than any of its pharma rivals. But the clinical debut of a new immune-boosting drug from its early-stage cancer pipeline Saturday suggests Merck is not heeding a hard lesson learned from its biggest blunder.

The new Merck drug, called MK-1454, shows no evidence that it can kill cancer cells when injected into patients on its own, as a monotherapy. But when MK-1454 was used in combination with Merck’s checkpoint inhibitor Keytruda, the tumors in a small number of patients got smaller.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.